>Cell-based Assay Verified Siglec-15 Protein
Siglec-15 is a member of the sialic acid-binding Ig-like lectin (Siglecs) family and is expressed in M2 macrophages, myeloid cells, dendritic cells, B cells, and osteoclasts. Siglec-15 can continuously inhibit the activity of T cells and exhibits the main features of normalized cancer immunotherapy. Related studies have shown that Siglec-15 is the major immunosuppressive factor in most PD-L1 negative tumor patients. And the anti-cancer effect of this target is likely to be mutually exclusive with PD-L1. In tumor cells, the expression level of siglec-15 is low when PD-L1 expression is high. For those cancer patients who are not effective in PD-1/PD-L1 treatment, Siglec-15 may bring them a new choice of immunotherapy.
High bioactivity Siglec-15 protein can help drugs development. The bioactivity of Siglec-15 protein developed by ACROBiosystems is verified by Cell based assay/BLI /SPR /ELISA, and the corresponding protocols are provided for free.
Cell based assay
Biotinylated Human Siglec-15, Fc,Avitag (Cat. No. SG5-H82F5) inhibits Anti-CD3-induced proliferation of PBMC. The ED50 for this effect is 0.48-0.57 μg/mL.
Loaded Anti-Siglec-15 MAb (Mouse IgG) on AMC Biosensor, can bind Human Siglec-15, Fc Tag (Cat. No. SG5-H5253) with an affinity constant of 59.7 pM as determined in BLI assay (ForteBio Octet Red96e).
Immobilized Neu5Ac(a2-6)GalNAc-PAA-biotin on SA Chip can bind Human Siglec-15, Fc Tag (Cat. No. SG5-H5253) with an affinity constant of 4.49 μM as determined in a SPR assay (Biacore T200).
Immobilized Mouse Human chimeric MAb (5G12, Human IgG1) at 5 μg/mL (100 μL/well) can bind Biotinylated Human Siglec-15, Fc,Avitag (Cat. No. SG5-H82F5) with a linear range of 0.4-3 ng/mL.
|Molecule||Cat. No.||Host||Product Description||Structure|
This web search service is supported by Google Inc.